title: Cosmetic regional conjunctivectomy with postoperative mitomycin C application with or without bevacizumab injection.
abstract: OBJECTIVE
  To evaluate the complications of cosmetic wide conjunctivectomy and postoperative topical mitomycin C application with or without bevacizumab injection.
  
  
  METHODS
  Cross-sectional cohort study.
  
  
  METHODS
  Medical records of 1713 consecutive subjects who received cosmetic wide conjunctivectomy plus postoperative topical mitomycin C by a single surgeon at a single center with or without bevacizumab injection from November 2007 to May 2010 were reviewed. A telephone interview was conducted with 557 of the subjects who could be contacted and agreed to participate in the study. Complications, recurrences, and patient satisfaction were the main outcome measures.
  
  
  RESULTS
  A total of 1713 consecutive patients underwent cosmetic wide conjunctivectomy to treat conjunctival hyperemia. Ocular diagnoses in the medical records at the time of surgery included hyperemia (8.8%), pterygium (14.0%), dry eye (3.5%), pinguecula (1.5%), and conjunctival disorder (23.3%). For the remaining 48.9% of subjects, the diagnosis was not mentioned, or the surgical procedure was for cosmetic purposes. Patients were followed for a mean of 10.9 months (range, 0-30.3 months). The overall complication rate was 82.9%, of which 55.6% were considered severe (fibrovascular conjunctival tissue proliferation, 43.8%; scleral thinning, 4.4%; scleral thinning with calcified plaques, 6.2%; intraocular pressure elevation, 13.1%; diplopia, 3.6%; and recurrence of hyperemic conjunctiva, 28.1%).
  
  
  CONCLUSIONS
  Cosmetic wide conjunctivectomy plus postoperative topical mitomycin C with or without bevacizumab injection has a high rate of complications and reoperations.
authors.affiliation: Department of New Health Technology Assessment, National Evidence-Based Healthcare Collaboration Agency, Seoul, South Korea.
authors.forename: Seonheui
authors.initials: S
authors.lastname: Lee
authors.affiliation: Department of New Health Technology Assessment, National Evidence-Based Healthcare Collaboration Agency, Seoul, South Korea.
authors.forename: Jeongae
authors.initials: J
authors.lastname: Go
authors.affiliation: Department of Ophthalmology, Severance Hospital, Institute of Vision Research, Yonsei University College of Medicine, Seoul, South Korea.
authors.forename: Soolienah
authors.initials: S
authors.lastname: Rhiu
authors.affiliation: Stulting Research Center, Woolfson Eye Institute, Atlanta, Georgia.
authors.forename: R Doyle
authors.initials: RD
authors.lastname: Stulting
authors.affiliation: Department of New Health Technology Assessment, National Evidence-Based Healthcare Collaboration Agency, Seoul, South Korea.
authors.forename: Min
authors.initials: M
authors.lastname: Lee
authors.affiliation: Department of New Health Technology Assessment, National Evidence-Based Healthcare Collaboration Agency, Seoul, South Korea.
authors.forename: Sunyoung
authors.initials: S
authors.lastname: Jang
authors.affiliation: Department of New Health Technology Assessment, National Evidence-Based Healthcare Collaboration Agency, Seoul, South Korea.
authors.forename: Sangmoo
authors.initials: S
authors.lastname: Lee
authors.affiliation: Department of Ophthalmology, Daegu Catholic University Medical Center, Seoul, South Korea.
authors.forename: Hyung Joon
authors.initials: HJ
authors.lastname: Kim
authors.affiliation: Division of Cornea, Department of Ophthalmology, Sungkyunkwan University School of Medicine, Seoul, South Korea.
authors.forename: Eui Sang
authors.initials: ES
authors.lastname: Chung
authors.affiliation: Department of Family Medicine, Kangdong Sacred Heart Hospital, Seoul, South Korea.
authors.forename: Sooyoung
authors.initials: S
authors.lastname: Kim
authors.affiliation: Department of Ophthalmology, Severance Hospital, Institute of Vision Research, Yonsei University College of Medicine, Seoul, South Korea. Electronic address: seoky@yuhs.ac.
authors.forename: Kyoung Yul
authors.initials: KY
authors.lastname: Seo
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000477:Alkylating Agents / Q000009:adverse effects / Q000627:therapeutic use*; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000009:adverse effects; D000068258:Bevacizumab; D003228:Conjunctiva / Q000187:drug effects*; D003229:Conjunctival Diseases / Q000601:surgery*; D003430:Cross-Sectional Studies; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000009:adverse effects / Q000627:therapeutic use*; D017060:Patient Satisfaction; D011183:Postoperative Complications; D012086:Reoperation; D012189:Retrospective Studies; D013518:Surgery, Plastic; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D055815:Young Adult
chemical_list: D000477:Alkylating Agents; D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D016685:Mitomycin